Clinical Trials Browser

Phase 1/2 × INDUSTRY × dubermatinib × Clear all

NCT03572634 2023-11-09

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Phase 1/2 Terminated

3 enrolled 7 charts

LymphoidOther hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell